GET DAILY SIGNALSREPL Stock Climbs +58% as TUDRIQEV Launch Gains Early Traction
Key Takeaways
- REPL shares climbed roughly 58% over the past 30 days, from about $13.07 to $20.66, as the company's first commercial launch gained early traction.
- The rally was fueled by the October 6 commercial debut of TUDRIQEV (vusolimogene oderparepvec) for advanced melanoma and stronger-than-expected early adoption.
- Fiscal second-quarter results reported on October 28 showed a narrowing net loss of $57.1 million and a cash position of $307.8 million.
- Analysts reacted positively, with Wedbush reiterating a Buy rating and Leerink Partners raising its price target to $31.
- Over the trailing quarter, shares have risen roughly 73% as Replimune transitioned from a clinical-stage to a commercial-stage biotechnology company.
- For additional detail, explore Replimune's Price Targets, Earnings, and Forecast pages.
Replimune Group (REPL) Company Overview and Market Position
Replimune Group, Inc. is a biotechnology company developing oncolytic immunotherapies built on its proprietary RPx platform, which uses an engineered herpes simplex virus (HSV-1) backbone to directly kill tumor cells and stimulate a systemic anti-tumor immune response. The company's lead product, TUDRIQEV (vusolimogene oderparepvec), received U.S. Food and Drug Administration (FDA) accelerated approval in August 2026 for use in combination with nivolumab to treat adults with unresectable advanced cutaneous melanoma whose disease has progressed on an anti-PD-1-based regimen.
The approval marked a pivotal transition: Replimune moved from a clinical-stage developer into a commercial-stage company, with TUDRIQEV representing the first FDA-approved product built on the RPx platform. I think investors follow the stock closely because the commercial launch, the confirmatory IGNYTE-3 trial, and pipeline candidates such as RP2 provide multiple potential value drivers for a company that has not yet recorded product revenue. To compare the setup against peers, I also checked this using Tickeron’s AI Screener.
Replimune Group (REPL) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, REPL advanced approximately 58%, rising from a closing price of $13.07 on October 2, 2026 to $20.66 in early November trading. The move accelerated sharply around October 28, when the stock gained more than 20% in a single session following the company's fiscal second-quarter earnings report and detailed launch commentary.
The quarterly picture is even more pronounced. Roughly three months ago, shares traded near $11.90 in early August, shortly after the FDA approval. Since then, the stock has climbed roughly 73% as investors repriced the company around its commercial launch and early prescription data. The broader trend reflects a multi-month recovery from the regulatory setbacks of the first half of 2026, followed by a steady upward repricing as launch execution came into focus.
What Drove REPL Stock Price in the Last 30 Days
The dominant catalyst was the commercial launch of TUDRIQEV. Replimune reported that TUDRIQEV was first delivered to patients with advanced melanoma on October 6, 2026, and that more than 15 institutions had prescribed the therapy within roughly three weeks. Management also indicated approximately 20 accounts had placed orders and implemented treatment workflows by the time of its earnings call, with more than 70% of targeted accounts engaged.
The company's fiscal second-quarter results, reported on October 28, reinforced the narrative. Replimune posted a net loss of $57.1 million, or $0.54 per share, narrowed from $83.1 million a year earlier, while research and development expense declined to $34.4 million. The company held $307.8 million in cash and equivalents as of September 30, 2026, and disclosed a list price of $450,000 per course of TUDRIQEV therapy before rebates and discounts.
Analyst actions amplified the move. Wedbush reiterated a Buy rating, and Leerink Partners raised its price target to $31, while the consensus rating among analysts covering the stock remained Buy. The sharp advance also coincided with elevated short interest, with shorts as a percentage of free float rising to roughly 34% after the earnings spike, suggesting that short-covering and repositioning contributed to the momentum.
What Drove REPL Stock Performance Over the Last Quarter
The quarterly trend was anchored by the FDA's accelerated approval of TUDRIQEV on August 6, 2026, which followed a Cellular, Tissue, and Gene Therapies Advisory Committee vote of 10-3 recommending approval. The approval represented a significant reversal after two prior complete response letters in July 2025 and April 2026 had sharply pressured the stock.
With the approval secured, Replimune built out its commercial organization and patient support infrastructure, completing a $141 million equity offering in August to fund the launch. The subsequent shift in focus from regulatory risk to commercial execution allowed the market to reprice the company around the addressable melanoma opportunity, where roughly half of patients do not respond to or progress after checkpoint blockade. The quarter's narrative, therefore, was one of de-risking, capitalization, and the first tangible steps toward generating product revenue.
REPL Stock Forecast Drivers: What Investors Should Watch Next
The most important near-term factor is the ongoing IGNYTE-3 confirmatory trial, which must verify clinical benefit for TUDRIQEV to maintain its accelerated approval. Investors will also monitor the first product revenue figures, expected to be reported in Replimune's fiscal third quarter, along with launch metrics such as the number of treating accounts, formulary access, and patient starts. Demand trends in the post-anti-PD-1 melanoma setting, reimbursement and rebate dynamics, and competitive developments in the melanoma space will all shape sentiment.
Additional catalysts include enrollment progress in the RP2 REVEAL Phase 2/3 trial in metastatic uveal melanoma and the company's ability to sustain its cash runway, which management indicated should fund operations for more than twelve months. The lingering securities class action related to the April 2026 complete response letter also remains an item to watch, though its near-term influence on fundamentals is limited. From what I see, keeping an eye on these milestones will be key to understanding the next phase of the story.
Exploring AI Tools for Trading Insights
In my view, automated strategies can complement fundamental research when evaluating names like REPL. I recently looked at Tickeron’s AI Trading Bots to see how different algorithms are positioned around biotech launches and momentum shifts. The platform offers a range of options with varying timeframes and risk profiles, which helps me quickly compare approaches without building everything from scratch. It is one way I stay on top of real-time signals while focusing on the broader narrative.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
REPL in upward trend: 10-day moving average moved above 50-day moving average on November 02, 2026
The 10-day moving average for REPL crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on REPL as a result. In 67 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for REPL just turned positive on October 26, 2026. Looking at past instances where REPL's MACD turned positive, the stock continued to rise in 43 of 49 cases over the following month. The odds of a continued upward trend are 88%.
REPL moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +12.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where REPL advanced for three days, in 185 of 245 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where REPL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
REPL broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for REPL entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. REPL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (18.417) is normal, around the industry mean (3.104). P/E Ratio (-6.556) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. REPL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of oncolytic immunotherapies
Industry Biotechnology
Advertisement